Department of Medicine, Liver Center, Beth Israel Deaconess Medical Center, Harvard Medical School, 110 Francis Street, Suite 4A, Boston, MA 02215, USA.
Department of Medicine, Liver Center, Beth Israel Deaconess Medical Center, Harvard Medical School, 110 Francis Street, Suite 4A, Boston, MA 02215, USA.
Gastroenterol Clin North Am. 2019 Jun;48(2):281-289. doi: 10.1016/j.gtc.2019.02.002. Epub 2019 Apr 1.
All chronic liver disease can lead to liver fibrosis. Assessment of the severity of liver fibrosis is central to making treatment and management decisions. Liver biopsy, the gold standard for liver fibrosis assessment, is invasive and carries risks of complications and sampling errors. The use of noninvasive elastography-based radiologic methods of liver fibrosis determination is limited to centers that have the capabilities. Laboratory liver fibrosis determinations, both general clinical scoring systems and combination biomarker panels, are accessible to a wider population of clinicians for identifying patients at low risk of advanced fibrosis who do not need liver biopsies.
所有慢性肝脏疾病均可导致肝纤维化。肝纤维化严重程度的评估是制定治疗和管理决策的关键。肝活检是肝纤维化评估的金标准,但具有侵袭性,且存在并发症和取样误差的风险。基于影像学的非侵入性弹性测定法在确定肝纤维化方面的应用仅限于有相关能力的中心。实验室肝纤维化检测,包括一般临床评分系统和联合生物标志物检测,可为更多的临床医生提供服务,以识别低风险进展性纤维化患者,这些患者无需进行肝活检。